Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Common Equity (2019 - 2026)

InMed Pharmaceuticals has reported Common Equity over the past 5 years, most recently at $9.6 million for Q4 2025.

  • For Q4 2025, Common Equity rose 55.09% year-over-year to $9.6 million; the TTM value through Dec 2025 reached $9.6 million, up 55.09%, while the annual FY2025 figure was $13.4 million, 45.93% up from the prior year.
  • Common Equity for Q4 2025 was $9.6 million at InMed Pharmaceuticals, down from $11.6 million in the prior quarter.
  • Over five years, Common Equity peaked at $15.2 million in Q3 2021 and troughed at -$9.6 million in Q3 2023.
  • A 5-year average of $9.8 million and a median of $11.0 million in 2022 define the central range for Common Equity.
  • Biggest five-year swings in Common Equity: plummeted 187.01% in 2023 and later surged 187.65% in 2024.
  • Year by year, Common Equity stood at $14.2 million in 2021, then rose by 1.18% to $14.3 million in 2022, then decreased by 10.9% to $12.8 million in 2023, then plummeted by 51.6% to $6.2 million in 2024, then surged by 55.09% to $9.6 million in 2025.
  • Business Quant data shows Common Equity for INM at $9.6 million in Q4 2025, $11.6 million in Q3 2025, and $13.4 million in Q2 2025.